Sandoz US News

sandoz_us_news.jpg

Sandoz announces US launch of GlatopaTM, the first generic competitor to Copaxone® 20mg

Holzkirchen, Germany, June 18, 2015 – Sandoz, a Novartis company, today announced the US launch of GlatopaTM, the first generic version of Teva’s Copaxone® (glatiramer acetate injection) 20 mg/ml one-time-daily multiple sclerosis therapy. hydrochloride extended release tablets, a generic version of INTUNIV®, which is currently marketed by Shire Pharmaceuticals.

Sandoz launches generic version of INTUNIV® extended release tablets in the US

Princeton, New Jersey, June 4, 2015 – Sandoz today announced the US market introduction of guanfacine hydrochloride extended release tablets, a generic version of INTUNIV®, which is currently marketed by Shire Pharmaceuticals.

Sandoz enters agreement to commercialize two ready-to-use infusion products in the United States

Sandoz today announced the signing of an exclusive license and supply agreement with BioQuiddity Incorporated, a specialty pharmaceutical company, under which Sandoz has the right to market Under the agreement, BioQuiddity is responsible for obtaining the requisite regulatory approvals and supplying the unit-dose infusion systems, and Sandoz is responsible for marketing and commercializing the products. Financial details of the agreement were not disclosed.

Product Catalog

Use our Product Catalog tool to search our database for information regarding a specific Sandoz product in the US.

 

Sandoz Careers

sandoz_careers.jpg

Our people are our greatest resource. We are always looking for new colleagues to share in our passion and commitment to making the world a healthier place.

Slideshow Background Images